Samath Jamie, Executive Vice President and Chief Financial Officer of Intuitive Surgical Inc . (NASDAQ:ISRG), a $203.8 billion medical technology company trading near its 52-week high, recently sold a significant portion of the company's stock. According to InvestingPro data, ISRG shares have delivered an impressive 51.4% return over the past year. According to the latest SEC filings, Jamie sold a total of 6,988 shares on January 28 and 29, with the sale prices ranging from $566.6 to $575.0 per share. This transaction amounted to a total value of approximately $4,007,891.
Additionally, Jamie exercised options to acquire shares at prices between $208.9 and $347.4167, totaling $227,990. Following these transactions, Jamie's direct ownership now stands at 2,630 shares. These transactions were conducted under a pre-established trading plan compliant with SEC Rule 10b5-1, set to expire on May 6, 2025.
In other recent news, Intuitive Surgical has been the focus of numerous analyst upgrades and positive outlooks, following a robust fourth quarter. RBC Capital Markets maintained an Outperform rating with a price target of $641.00, citing the company's strong performance in the fourth quarter of 2024, which exceeded expectations with a 10% and 24% beat on revenue and earnings per share, respectively. The company also provided procedure guidance for 2025, projecting a 13-16% year-over-year increase.
Piper Sandler increased the price target on Intuitive Surgical shares to $670, maintaining an Overweight rating. This followed the company's impressive fourth-quarter earnings report. Oppenheimer maintained a Perform rating on the company's stock, despite the company's strong fourth-quarter results and a significant distribution agreement worth €290 million, expected to close by 2026.
Bernstein reaffirmed an Outperform rating for Intuitive Surgical, setting a price target of $700, based on the company's strong financial performance in the last quarter. Lastly, Truist Securities updated its outlook on Intuitive Surgical, increasing the price target to $666, while maintaining a Buy rating. These recent developments reflect a range of perspectives among analysts, with some expressing optimism about the company's future growth prospects, and others expressing a more cautious outlook due to external pressures and uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.